
The European Medicines Agency has completed a safety review of Roche’s MabThera convened after bacterial contamination was discovered in bioreactors …

Biocatalyst specialist Codexis has signed a three-year extension of its catalyst and process development collaboration with Merck to develop enzymes …
FDA inspections of a manufacturing facility for Roche/Genentech’s cancer drug Avastin (bevacizumab) uncovered a number of deficiencies which could increase …
North American contract manufacturer Patheon is winding down some operations at its facility in Swindon, UK, with the aim of …

BASF has said it plans to build a new manufacturing facility for formic acid at its production site in Louisiana, …
Novartis chief executive Joe Jimenez has said that production at the firm’s troubled consumer health plant in Lincoln, Nebraska, will …

The US Food and Drug Administration (FDA) has approved a new, more environmentally-friendly manufacturing process for Merck & Co’s diabetes …
Baxter International has unveiled plans to build a major new manufacturing complex for its plasma-based therapies in Atlanta in the …
China’s State Food and Drug Administration (SFDA) has banned the sale of 13 medicines thought to be manufactured using contaminated …
Merck has teamed up with catalyst specialist Codexis to develop a more efficient manufacturing process for recently-approved hepatitis C treatment …
Pharmaceutical manufacturers are acting ‘prematurely’ when asking excipient suppliers to provide metal impurity levels, according to a new position paper …
French processing equipment supplier Novasep has opened a new facility in China to meet what it says is increasing demand …
Novartis has selected Turkey as its headquarters for central Asia, the Middle East and Africa and intends to set up …

Teva has said it plans to sell a manufacturing facility in Quebec, Canada, to US contract manufacturing organisation Halo Pharmaceutical. …

The US Food and Drug Administration has asked Merck KGaA to undertake a ‘comprehensive and global assessment’ of its manufacturing …